Furthering its research initiatives, during the year, Zydus Cadila company entered into a collaborative research agreement with the Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology (IMTECH) to identify new drug candidates for the treatment of drug-resistant infections.
The company also made progress with its key research molecules, Desidustat, the Investigational New Drug targetted at treating anemia in Chronic Kidney Disease (CKD) patients and Saroglitazar for the treatment of Non-Alcoholic SteatoHepatitis (NASH). During the year, the company also acquired 51% stake in Dehradun-based Windlas Healthcare Private Limited (WHPL).
Strengthening its regulatory pipeline, the company filed 29 ANDAs during the year with the US FDA, taking the cumulative filings to 360. The company received 74 ANDA approvals taking the total to 254 product approvals.